Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
0(0%)
Results Posted
71%(5 trials)
Terminated
2(18%)

Phase Distribution

Ph not_applicable
1
9%
Ph phase_1
8
73%
Ph phase_2
2
18%

Phase Distribution

8

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
8(72.7%)
Phase 2Efficacy & side effects
2(18.2%)
N/ANon-phased studies
1(9.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

63.6%

7 of 11 finished

Non-Completion Rate

36.4%

4 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(7)
Terminated(4)

Detailed Status

Completed7
Terminated2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
77.8%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (72.7%)
Phase 22 (18.2%)
N/A1 (9.1%)

Trials by Status

terminated218%
completed764%
withdrawn218%

Recent Activity

0 active trials
Showing 5 of 11
terminatednot_applicable

Endometrial Rejuvenation Study

NCT04045821
completedphase_1

Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100

NCT00479115
completedphase_1

An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

NCT00322127
withdrawnphase_2

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

NCT04058145
completedphase_1

Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies

NCT00241358
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT04045821Not Applicable

Endometrial Rejuvenation Study

Terminated
NCT00479115Phase 1

Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100

Completed
NCT00322127Phase 1

An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

Completed
NCT04058145Phase 2

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

Withdrawn
NCT00241358Phase 1

Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies

Completed
NCT00914849Phase 2

Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies

Completed
NCT00733824Phase 1

Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma

Completed
NCT01026987Phase 1

Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant

Completed
NCT00512252Phase 1

AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia

Completed
NCT01655875Phase 1

AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia

Terminated
NCT00396968Phase 1

AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS

Withdrawn

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11